Screener
Relmada Therapeutics, Inc. RLMD Q3 2026 earnings
Reported November 12, 2026 · After market close
EPS-$0.12Beat by $0.02
EPS estimate-$0.15
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Relmada Therapeutics, Inc. report Q3 2026 earnings?
- Relmada Therapeutics, Inc. (RLMD) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Relmada Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Relmada Therapeutics, Inc. reported eps of $-0.12 for Q3 2026.
- Did Relmada Therapeutics, Inc. beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-0.14 by $0.02.
- How did Relmada Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 60.0% from $-0.30.
- Where can I find Relmada Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001213900-26-118933) and the 10-Q periodic report (0001213900-26-118916) directly on SEC EDGAR. The filing index links above go to sec.gov.
